Patient characteristics in the AF1q study population
. | Low AF1q expression* . | High AF1q expression† . | P . |
|---|---|---|---|
| No. | 43 | 21 | NA |
| Median age, y | 8.6 | 8.3 | .721 |
| Median WBC count per mm3 | 637 000 | 437 000 | .403 |
| No. of males (%) | 21 (49) | 13 (62) | .473 |
| No. of nonwhites (%) | 10 (23) | 7 (33) | .578 |
| Intensive induction, no. (%) | 25 (58) | 15 (71) | .45 |
| CR rate, % | 70 | 65 | .922 |
| FAB classification, no. (%) | .057 | ||
| M0 | 1 (2.3) | 0 (0) | .99 |
| M1 | 4 (9.3) | 9 (42.8) | .003 |
| M2 | 12 (27.9) | 4 (19.0) | .547 |
| M3 | 3 (12) | 1 (4.8) | .99 |
| M4 | 15 (43.8) | 4 (19.0) | .251 |
| M5 | 6 (13.9) | 2 (9.5) | .99 |
| M6 | 2 (4.6) | 0 (0) | .99 |
| M7 | 0 (0) | 1 (4.8) | .328 |
| Cytogenetics, no. (%) | |||
| No. | 25 | 12 | .569 |
| Normal | 8 (32) | 6 (50) | .47 |
| t(15;17) | 2 (8) | 1 (8.3) | .99 |
| t(8;21) | 3 (12) | 1 (8.3) | .99 |
| 11q23 | 6 (24)‡ | 1 (8.3)§ | .389 |
| Del 7 | 0 (0) | 0 (0) | NA |
| Del 5 | 0 (0) | 1 (8.3) | .324 |
| Others | 5 (20) | 1 (8.3) | .641 |
| Mutation status, no. (%) | |||
| No. | 43 | 21 | .082 |
| No mutation | 23 (53.5) | 10 (47.6) | .791 |
| K-ras | 3 (7) | 2 (9.5) | .99 |
| N-ras | 9 (21) | 0 (0) | .025 |
| Flt3/ITD | 5 (11.6) | 5 (23.8) | .275 |
| Flt3/ALM | 2 (4.6) | 3 (14.3) | .320 |
| All FLT3 mutations | 7 (16.2) | 8 (38.1) | .066 |
| Survival/relapse | |||
| 8-year OS from diagnosis, % | 50% | 19% | .01 |
| 8-year DFS from remission, % | 50% | 0% | .001 |
| Relapse rate at 8 years, % | 50% | 100% | .002 |
. | Low AF1q expression* . | High AF1q expression† . | P . |
|---|---|---|---|
| No. | 43 | 21 | NA |
| Median age, y | 8.6 | 8.3 | .721 |
| Median WBC count per mm3 | 637 000 | 437 000 | .403 |
| No. of males (%) | 21 (49) | 13 (62) | .473 |
| No. of nonwhites (%) | 10 (23) | 7 (33) | .578 |
| Intensive induction, no. (%) | 25 (58) | 15 (71) | .45 |
| CR rate, % | 70 | 65 | .922 |
| FAB classification, no. (%) | .057 | ||
| M0 | 1 (2.3) | 0 (0) | .99 |
| M1 | 4 (9.3) | 9 (42.8) | .003 |
| M2 | 12 (27.9) | 4 (19.0) | .547 |
| M3 | 3 (12) | 1 (4.8) | .99 |
| M4 | 15 (43.8) | 4 (19.0) | .251 |
| M5 | 6 (13.9) | 2 (9.5) | .99 |
| M6 | 2 (4.6) | 0 (0) | .99 |
| M7 | 0 (0) | 1 (4.8) | .328 |
| Cytogenetics, no. (%) | |||
| No. | 25 | 12 | .569 |
| Normal | 8 (32) | 6 (50) | .47 |
| t(15;17) | 2 (8) | 1 (8.3) | .99 |
| t(8;21) | 3 (12) | 1 (8.3) | .99 |
| 11q23 | 6 (24)‡ | 1 (8.3)§ | .389 |
| Del 7 | 0 (0) | 0 (0) | NA |
| Del 5 | 0 (0) | 1 (8.3) | .324 |
| Others | 5 (20) | 1 (8.3) | .641 |
| Mutation status, no. (%) | |||
| No. | 43 | 21 | .082 |
| No mutation | 23 (53.5) | 10 (47.6) | .791 |
| K-ras | 3 (7) | 2 (9.5) | .99 |
| N-ras | 9 (21) | 0 (0) | .025 |
| Flt3/ITD | 5 (11.6) | 5 (23.8) | .275 |
| Flt3/ALM | 2 (4.6) | 3 (14.3) | .320 |
| All FLT3 mutations | 7 (16.2) | 8 (38.1) | .066 |
| Survival/relapse | |||
| 8-year OS from diagnosis, % | 50% | 19% | .01 |
| 8-year DFS from remission, % | 50% | 0% | .001 |
| Relapse rate at 8 years, % | 50% | 100% | .002 |